Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 5/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2348949 | 0.80 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL3871568 | 0.79 | SMN1; SMN2 (0.53) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL3869328 | 0.78 | MAPT (0.50) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL3864855 | 0.78 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL6512906 | 0.76 | PDE4A (0.86) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL5353533 | 0.76 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL5765941 | 0.75 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL14423584 | 0.75 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL5103773 | 0.75 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL5563021 | 0.75 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682534-A2 | PYRIMIDIN-4-ONE COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050197327-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2005-09-08 | — | — | US | disclosed |
| WO-2005041888-A2 | PYRIMIDIN-4-ONE COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197327-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | PDE4A 2495/4885PDE4B 2576/4885PDE4C 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.